These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7089017)

  • 21. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

  • 22. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic cerebrovascular disorders: a clinical study with cyclandelate.
    Bassi S; Albizzati MG; Sbacchi M; Frattola L
    Br J Clin Pract; 1984 Oct; 38(10):344-9. PubMed ID: 6498057
    [No Abstract]   [Full Text] [Related]  

  • 24. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 28. Multifocal infarct dementia treated by cyclandelate and monitored by quantitative EEG.
    Harding GF; Hall P; Young J; Smith GA
    Angiology; 1978 Feb; 29(2):139-40. PubMed ID: 347986
    [No Abstract]   [Full Text] [Related]  

  • 29. The anti-hypoxaemic effect of cyclandelate in man measured in human volunteers using computer-assisted oculodynamic methodology.
    Schaffler K
    Br J Clin Pract Suppl; 1984; 34():51-7. PubMed ID: 6430324
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cyclospasmol (mandelic acid ester of 3,5,5-trimethylcyclohexanol) in therapy of skin diseases].
    DOORNINK FJ
    Geneeskd Gids; 1953 Jun; 31(12):247-51. PubMed ID: 13083900
    [No Abstract]   [Full Text] [Related]  

  • 31. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
    de Halleux F
    Drugs; 1987; 33 Suppl 2():114-9. PubMed ID: 3622305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclandelate in diabetic radiculoneuropathy.
    van der Drift JH
    Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of peripheral vascular diseases with cyclospasmol (mandelic acid ester of 3, 5, 5-trimethylcyclohexanol).
    VAN WIJK TW
    Angiology; 1953 Apr; 4(2):103-13. PubMed ID: 13040814
    [No Abstract]   [Full Text] [Related]  

  • 36. Investigation into 3.5.5-trimethylcyclohexyl mandelate (cyclospasmol).
    EIJKEL G; ERNSTING MJ; REKKER RF; NAUTA WT
    Pharm Weekbl; 1956 Feb; 91(3):81-90. PubMed ID: 13310218
    [No Abstract]   [Full Text] [Related]  

  • 37. The melting-point of cyclospasmol and the quantitative determination of small amounts of 3.5.5.-trimethylcyclohexyl phenylglyoxylate in same.
    REKKER RF; ERNSTING MJ; NAUTA WT
    Pharm Weekbl; 1956 Jan; 91(1):1-6. PubMed ID: 13310216
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical efficacy of Cyclospasmol: a review of the literature.
    Blakemore CB
    Br J Clin Pract Suppl; 1984; 34():3-9. PubMed ID: 6430319
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders.
    Albizzati MG; Bassi S; Sbacchi M; Frattola L
    Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.